NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode Performed at Mayo Clinic
EDEN PRAIRIE, Minn., May 10, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its first clinical case using the Evo® sEEG electrode was performed by Dr. Jamie Van Gompel at Mayo Clinic. Using a non-robotic stereotactic frame system, Evo electrodes were implanted successfully and met the Company’s product performance objectives.
- Using a non-robotic stereotactic frame system, Evo electrodes were implanted successfully and met the Company’s product performance objectives.
- We are ecstatic with the initial performance of our Evo sEEG electrodes which confirmed the results of many years of testing on the device.
- While we previously used the device intraoperatively, this was the first clinical case that was cleared by the FDA for less than 30 day use.
- NeuroOne believes there is a significant opportunity to expand market adoption of sEEG technology with broad U.S. distribution of its Evo product line.